You are here: Industry Insights > lung cancer

News List

J&J's quest to detect lung cancer before it emerges fiercebiotech
April 28, 2019
Smoking causes injuries in the respiratory tract that can evolve into lung cancer. Researchers from Johnson & Johnson Innovation and Boston University wondered whether it might be possible to prevent lung lesions from becoming cancerous ...
FDA expands Keytruda label to include stage 3 and 4 non-small cell lung cancer pharmafile
April 23, 2019
MSD has revealed that its anti-PD-1 therapy Keytruda (pembrolizumab) has received expanded indication from the FDA to include the first-line treatment of stage 3 or metastatic non-small cell lung cancer (NSCLC).
SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer pharmafocusasia
April 19, 2019
SK Biopharmaceuticals and twoXAR Sign Collaboration Agreement to Discover and Develop First-In-Class Treatments for Non-Small Cell Lung Cancer
AZ finds lack of lung cancer info available for patients pharmatimes
April 16, 2019
New AstraZeneca research has shown significant gaps in online sources of information for lung cancer patients.
VolitionRx extends clinical trial programme in lung cancer biospectrumasia
April 08, 2019
VolitionRx Limited has announced that it has added to its extensive clinical trial program with the execution of ……
BMS, clinging to Opdivo's lung cancer share, highlights long-term data fiercepharma
April 04, 2019
After a hard blow to its hopes in previously untreated lung cancer, Bristol-Myers Squibb is clinging to its share of the second-line market.
Blueprint Medicines Announces Accelerated Regulatory Submission Plans and Recent Clinical Progress firstwordpharma
March 28, 2019
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to expedite development of avapritinib, BLU-667 and BLU-782 based on recent c
FDA approves Roche's Tecentriq in combination with chemotherapy for the initial treatment of adults with extensive-stage small cell lung cancer worldpharmanews
March 21, 2019
Roche announced that FDA approved Tecentriq® (atezolizumab), in combination with carboplatin and etoposide (chemotherapy) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
Lilly’s combo therapy succeeds in the late-stage lung cancer study expressbpd
March 19, 2019
Previously untreated patients with metastatic non-small cell lung cancer taking a combination of Lilly’s Cyramza and Roche’s erlotinib went longer before their disease started to worsen
7 anti-PD-(L)1 antibodies in Phase III clinical trials: lung cancer is still an important indication competed for PharmaSources/1℃
March 06, 2019
Besides the above products mentioned, there are still 7 anti-PD-(L)1 antibodies in Phase III clinical trials, and lung cancer is still one of the important indications the most companies lay out.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page